Drug Profile
MS 28168
Latest Information Update: 31 Aug 2007
Price :
$50
*
At a glance
- Originator Nihon Schering
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Oct 1997 Preclinical development for Thrombosis in Japan (PO)